SAN DIEGO, California, July 2, 2026
Circular Genomics has unveiled CircPATH™, its proprietary circular RNA (circRNA) discovery and validation platform, following the publication of a landmark Nature Medicine study demonstrating breakthrough performance in the early detection and prediction of Alzheimer’s disease (AD). The newly launched platform is designed to transform precision neurology by enabling blood-based detection of Alzheimer’s years before clinical symptoms appear, while significantly outperforming current gold-standard biomarkers. The study demonstrated that circRNA biomarkers not only detect Alzheimer’s disease with exceptional accuracy but also predict progression from cognitively normal individuals to symptomatic disease, providing clinicians and researchers with a powerful new approach for early diagnosis, patient stratification, and therapeutic development. Validated across nearly 2,400 individuals in three independent clinical cohorts, CircPATH™ represents a major advancement in precision medicine by translating novel RNA biology into clinically actionable molecular diagnostics capable of improving disease management and accelerating neurodegenerative drug development.
CircPATH™ Delivers Superior Accuracy Over Existing Alzheimer’s Biomarkers
The landmark Nature Medicine publication established that Circular Genomics’ CircPATH™ platform significantly outperformed the current clinical standard biomarker plasma pTau217 in detecting Alzheimer’s disease. The proprietary 34-circular RNA biomarker signature achieved an impressive Area Under the Curve (AUC) of 0.945 for identifying biomarker-confirmed Alzheimer’s disease in symptomatic patients, compared with 0.877 for pTau217. When both biomarker approaches were combined, diagnostic performance increased further to an exceptional AUC of 0.967, approaching the accuracy of expensive PET imaging and invasive cerebrospinal fluid testing. Beyond diagnosis, CircPATH™ demonstrated remarkable predictive capability by identifying cognitively healthy individuals who later progressed to symptomatic Alzheimer’s disease.
The circRNA biomarkers achieved a hazard ratio of 2.92, representing a 61% stronger predictive performance than pTau217 alone. For predicting symptom development within five years, CircPATH™ delivered an AUC of 0.870, substantially outperforming pTau217, which achieved an AUC of 0.676. These findings position blood-based circular RNA biomarkers as one of the most promising non-invasive technologies for identifying patients at risk before irreversible neurological damage occurs.
Multi-Pathway circRNA Signatures Advance Precision Neurology
Advertisement
Unlike conventional biomarkers that primarily focus on amyloid and tau pathology, CircPATH™ captures multiple biological pathways simultaneously, offering a more comprehensive picture of Alzheimer’s disease progression. The identified circRNA signatures originate from brain-enriched molecules capable of crossing the blood-brain barrier, enabling a simple blood sample to reflect complex central nervous system biology. The biomarker panel incorporates signals linked to amyloid precursor protein (APP) regulation, synaptic dysfunction, neuroinflammation, protein aggregation, and several genome-wide association study (GWAS) risk genes, including PICALM and DNAJC6. This multi-pathway approach enables more accurate disease characterization while supporting precision medicine strategies that extend beyond diagnosis.
The technology also provides pharmaceutical companies with valuable tools for clinical trial enrichment, allowing researchers to identify patients most likely to progress, monitor treatment responses across multiple disease pathways, and optimize therapeutic development. These capabilities have the potential to reduce clinical trial duration, improve endpoint selection, and accelerate the development of next-generation Alzheimer’s therapies.
Platform Strengthens Precision Medicine Pipeline for Neurodegenerative Diseases
Following successful validation in three independent cohorts, including two Knight Alzheimer’s Disease Research Center (Knight-ADRC) cohorts and the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study, Circular Genomics is advancing a growing pipeline of circRNA-based diagnostic products targeting Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. The company intends to collaborate with biopharmaceutical companies, clinical research organizations, and academic medical centers to integrate CircPATH™-derived biomarkers into precision medicine programs and future drug development initiatives.
By enabling earlier disease detection, better patient stratification, and more accurate monitoring of treatment response, CircPATH™ addresses several longstanding challenges in neurodegenerative medicine. As demand continues to grow for reliable, minimally invasive biomarkers capable of identifying disease before symptom onset, Circular Genomics’ CircPATH™ platform has the potential to reshape Alzheimer’s diagnostics and support the development of more effective personalized therapies, reinforcing the expanding role of RNA-based precision medicine in modern neurological healthcare.
Source: Circular Genomics press release
